Vol. 5 No. 1 (2017): April 2017

Published: 2017-04-30

Editorial

Changing paradigm in recurrent ovarian cancer treatment

Sandro Pignata, Sabrina Chiara Cecere

3-6
- PDF

Review

Evolution and innovations in the systemic treatment landscape of renal cell carcinoma

Alessia Mennitto, Elena Verzoni, Giuseppe Procopio

7-11
- PDF

Pro & Cons editorial

Is there a role for intraoperative radiation therapy in resectable extremity soft tissue sarcoma beyond external beam radiation therapy?

Antonino De Paoli, Claudia Sangalli, Giacomo G. Baldi

12-14
- PDF

Breaking from the Lab

How to measure homologous recombination deficiency in ovarian cancer

Claudia Marchetti, Iain A. McNeish

15-20
- PDF

Clinical original article

Will the carboplatin-paclitaxel-bevacizumab combination become the preferred option as the first line in advanced cervical cancer? A small experience from a single oncologic Center

Raquel Bratos Lorenzo, Luisa Sánchez Lorenzo, Antonio González-Martín

21-24
- PDF
Olaparib as maintenance treatment in relapsed platinum-sensitive BRCA mutated ovarian cancer: real world experience in two Italian cancer Centers

Sabrina Chiara Cecere, Stefano Lepori, Marilena Di Napoli, Carmela Pisano, Sabrina Rossetti, Jole Ventriglia, Imma Paciolla, Giuseppa Maltese, Caterina Fontanella, Francesco Raspagliesi, Domenica Lorusso

25-30
- PDF

Meet the expert

Case 1 − A case of gynecological PEComa

Caterina Fontanella, Maria Luisa Carcangiu, Domenica Lorusso, Bruno Vincenti

31-34
- PDF
Case 2 – Ovarian small cell carcinoma: a case report and review of the literature

Vanda Salutari, Patricia Pautier

35-39
- PDF

Methodological corner

The role of subgroup analyses: results from the NOVA trial

Massimo Di Maio, Alice Bergamini

40-42
- PDF

Letter to the Editor

Letter to the Editor

Paolo A. Ascierto

43-44
- PDF